

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 December 2017 (14.12.2017)



(10) International Publication Number
WO 2017/211928 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/42 (2006.01)
C07K 14/735 (2006.01)

(21) International Application Number:

PCT/EP2017/063916

(22) International Filing Date:

08 June 2017 (08.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1610198.2 10 June 2016 (10.06.2016) GB
1702435.7 15 February 2017 (15.02.2017) GB

(71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: ADAMS, Ralph; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). CESKA, Thomas Allen; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DAVIES, Anna Marie; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 1UL (GB). HENRY, Alistair James; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). LIU, Xiaofeng; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). MCDONNELL, James Michael; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 1UL (GB). SUTTON, Brian John; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 1UL (GB). WESTWOOD, Marta Katarzyna; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-IgE ANTIBODIES

(57) Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).



WO 2017/211928 A1